Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.

Vlot MC, Klink DT, den Heijer M, Blankenstein MA, Rotteveel J, Heijboer AC

Bone11 Nov 2016Cited by 125 (Europe PMC)

PMID27845262DOI10.1016/j.bone.2016.11.008PepBankPUB-27845262

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyMechanism
In transgender adolescents, P1NP decreased during triptorelin pubertal suppression compared with pretreatment.
In plain wordsIn transgender adolescents, P1NP decreased during triptorelin treatment compared with pretreatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseP1NP during GnRHa treatment
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Change in P1NP (95% CI)
−74 to −50%
P1NP and ICTP, young transmen, p=0.02
Change in P1NP (95% CI)
−73 to −43%
P1NP and ICTP, young transwomen, p=0.008
Source sentences
Summary
We found a decrease of P1NP and 1CTP during GnRHa treatment, indicating decreased bone turnover (young transmen 95% CI -74 to -50%, p=0.02, young transwomen 95% CI -73 to -43, p=0.008).
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
Report a problemFND-2784526201
02HumanObservational studyMechanism
In transgender adolescents, ICTP decreased during triptorelin pubertal suppression compared with pretreatment.
In plain wordsIn transgender adolescents, ICTP decreased during triptorelin treatment compared with pretreatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseICTP during GnRHa treatment
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Change in ICTP (95% CI)
−74 to −50%
P1NP and ICTP, young transmen, p=0.02
Change in ICTP (95% CI)
−73 to −43%
P1NP and ICTP, young transwomen, p=0.008
Source sentences
Summary
We found a decrease of P1NP and 1CTP during GnRHa treatment, indicating decreased bone turnover (young transmen 95% CI -74 to -50%, p=0.02, young transwomen 95% CI -73 to -43, p=0.008).
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
Report a problemFND-2784526202
03HumanObservational studySafety outcome
In transgender adolescents, femoral neck BMAD remained unchanged during triptorelin pubertal suppression compared with pretreatment.
In plain wordsIn transgender adolescents, femoral neck bone density remained unchanged during triptorelin treatment compared with pretreatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFemoral neck BMAD during GnRHa treatment
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
The decrease in bone turnover upon GnRHa treatment was accompanied by an unchanged BMAD of FN and LS, whereas BMAD Z-scores of predominantly the LS decreased especially in the young transwomen.
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
Report a problemFND-2784526203
04HumanObservational studySafety outcome
In transgender adolescents, lumbar spine BMAD remained unchanged during triptorelin pubertal suppression compared with pretreatment.
In plain wordsIn transgender adolescents, lumbar spine bone density remained unchanged during triptorelin treatment compared with pretreatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLumbar spine BMAD during GnRHa treatment
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
The decrease in bone turnover upon GnRHa treatment was accompanied by an unchanged BMAD of FN and LS, whereas BMAD Z-scores of predominantly the LS decreased especially in the young transwomen.
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
Report a problemFND-2784526204
05HumanObservational studySafety outcome
In transgender adolescents, BMAD Z-scores decreased during triptorelin suppression, predominantly at the lumbar spine and especially in young transwomen.
In plain wordsIn transgender adolescents, bone density Z-scores decreased during triptorelin treatment, mainly at the lumbar spine, especially in young transwomen.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBMAD Z-scores during GnRHa treatment
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
The decrease in bone turnover upon GnRHa treatment was accompanied by an unchanged BMAD of FN and LS, whereas BMAD Z-scores of predominantly the LS decreased especially in the young transwomen.
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
Report a problemFND-2784526205

Studies that did not test the peptide alone4

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyMechanism
In transgender adolescents receiving triptorelin, P1NP decreased further 24 months after cross-sex hormone addition, except in older transmen.
In plain wordsIn transgender adolescents receiving triptorelin, P1NP decreased further 24 months after cross-sex hormone addition, except in older transmen.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseP1NP after addition of CSHT
Study
n: not reported in source
Comparator
Before addition of cross-sex hormones
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Twenty-four months after CSHT the BTMs P1NP and ICTP were even more decreased in all groups except for the old transmen.
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2784526206
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyMechanism
In transgender adolescents receiving triptorelin, ICTP decreased further 24 months after cross-sex hormone addition, except in older transmen.
In plain wordsIn transgender adolescents receiving triptorelin, ICTP decreased further 24 months after cross-sex hormone addition, except in older transmen.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseICTP after addition of CSHT
Study
n: not reported in source
Comparator
Before addition of cross-sex hormones
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Twenty-four months after CSHT the BTMs P1NP and ICTP were even more decreased in all groups except for the old transmen.
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2784526207
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In transgender adolescents receiving triptorelin plus cross-sex hormones, BMAD increased during cross-sex hormone therapy.
In plain wordsIn transgender adolescents, bone density increased after cross-sex hormones were added to triptorelin compared with before hormone addition.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBMAD during CSHT
Study
n: not reported in source
Comparator
Before addition of cross-sex hormones
Outcome group
Bone and joint · Musculoskeletal
Measurements
Change (95% CI)
0.1 to 0.6 not stated
lumbar spine, young transwomen, p=0.01; source does not say if this is BMAD or Z-score
Change (95% CI)
0.3 to 0.8 not stated
lumbar spine, old transwomen, p=0.04; source does not say if this is BMAD or Z-score
Source sentences
Summary
During CSHT BMAD increased and Z-scores returned towards normal, especially of the LS (young transwomen CI 95% 0.1 to 0.6, p=0.01, old transwomen 95% CI 0.3 to 0.8, p=0.04).
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2784526208
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In transgender adolescents receiving triptorelin plus cross-sex hormones, BMAD Z-scores returned towards normal, especially at the lumbar spine.
In plain wordsIn transgender adolescents, bone density Z-scores moved towards normal after cross-sex hormones were added to triptorelin, especially at the lumbar spine.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBMAD Z-scores during CSHT
Study
n: not reported in source
Comparator
Before addition of cross-sex hormones
Outcome group
Bone and joint · Musculoskeletal
Measurements
Change (95% CI)
0.1 to 0.6 not stated
lumbar spine, young transwomen, p=0.01; source does not say if this is BMAD or Z-score
Change (95% CI)
0.3 to 0.8 not stated
lumbar spine, old transwomen, p=0.04; source does not say if this is BMAD or Z-score
Source sentences
Summary
During CSHT BMAD increased and Z-scores returned towards normal, especially of the LS (young transwomen CI 95% 0.1 to 0.6, p=0.01, old transwomen 95% CI 0.3 to 0.8, p=0.04).
3 context sentences(design, population, supporting numbers)
Summary · context
Thirty four female-to-male persons (transmen) and 22 male-to-female persons (transwomen)were included.
Summary · context
All were treated with GnRHa triptorelin and CSHT was added in incremental doses from the age of 16years.
Summary · context
Transmen received testosterone esters (Sustanon, MSD) and transwomen received 17-β estradiol.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2784526209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.